Table 2.
Estradiol Pharmacokinetics by Route of Administration in Transgender Women
| Route of estradiol | N | Baseline GM [95% CI] | On F/TDF GM [95% CI] | On F/TDF versus baseline GMR [95% CI] | p | |
|---|---|---|---|---|---|---|
| AUClast (h × pg/mL) | Oral/sublingual | 13 | 1,531 [1,110–2,112] | 1,434 [980–2,099] | 0.94 [0.70–1.25] | .630 |
| Intramuscular | 12 | 67,386 [46,530–97,588] | 53,666 [36,979–77,883] | 0.79 [0.63–1.01] | .056 | |
| Cmax (pg/mL) | Oral/sublingual | 13 | 191 [357–102] | 161 [307–85] | 0.85 [0.53–1.34] | .443 |
| Intramuscular | 12 | 614 [443–852] | 524 [346–793] | 0.85 [0.61–1.18] | .308 |
AUC, area under the curve; CI, confidence interval; GM, geometric mean; GMR, geometric mean ratio; F/TDF, emtricitabine/tenofovir disoproxil fumarate.